Highlights of weekly biotech stock moves

Epigenomics AG (Xetra:ECX) fell €2.62 (42%) to €3.69 last week after saying it received a response letter from FDA for a PMA for its Epi proColon 2.0 blood-based colorectal cancer (CRC) screening test. The company said FDA requested additional data demonstrating the test would increase compliance for CRC screening in patients who do not undergo screening by recommended methods.

Halozyme Therapeutics Inc. (NASDAQ:HALO) gained $0.99 (13%) to $8.89 last week after FDA lifted a clinical hold on the Phase II Study 202 of PEGPH20 in combination with Abraxane nab-paclitaxel from Celgene Corp. (NASDAQ:CELG) and gemcitabine for first-line treatment of pancreatic cancer (see B28). ...